Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

146.38 +1.81 (+1.25%)
Official Closing Price Updated: 7:00 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,978,848
Open 144.79
Bid (Size) 146.00 (4)
Ask (Size) 146.38 (1)
Prev. Close 144.57
Today's Range 144.73 - 147.07
52wk Range 130.96 - 168.11
Shares Outstanding N/A
Dividend Yield 4.04%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Cerevel Therapeutics Holdings Is Moving After-Hours
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading higher in Wednesday's after-hours session after AbbVie Inc. (NYSE: ABBV) announced it will acquire the company for a total equity... 
Via Benzinga
7 High-Dividend Stocks to Buy for a Lifetime of Passive Income
These high-dividend stocks are among the biggest beneficiaries of current mega trends, and investors can leverage them for big gains. 
Via InvestorPlace

Performance

YTD
-9.85%
-9.85%
1 Month
+3.67%
+3.67%
3 Month
+0.53%
+0.53%
6 Month
+7.72%
+7.72%
1 Year
-10.59%
-10.59%

More News

Read More
Small Cap, Big Potential: 3 Russell 2000 Stocks to Watch
Via InvestorPlace
Decoding AbbVie's Options Activity: What's the Big Picture?
Via Benzinga
3 Stocks at the Forefront of Personalized Medicine Trend
Via InvestorPlace
Analyst Ratings for AbbVie
Via Benzinga
Health Care Company AbbVie Announces Acquisition of Immunogen
Via Benzinga
AbbVie Should Consider a Dividend Cut -- Here's Why
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
From Brodsky & Smith LLC
Via GlobeNewswire
ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note
Via Benzinga
AbbVie's Big Buy Of ImmunoGen Opens Doors For Potential Investment Gains
Via Talk Markets
2 Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
Via MarketBeat
Topics Bonds
Exposures Debt Markets
5 S&P 500 Stocks That Pay a Generous Dividend
Via The Motley Fool
Topics Stocks
Exposures US Equities
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
These biotechs targeting multiple neurodegenerative diseases
Via MarketBeat
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Via Talk Markets
Why Abbvie Stock Popped Today
Via The Motley Fool
ImmunoGen's Flagship Cancer Therapy Draws AbbVie's Attention With $10.1B Deal
Via Benzinga
Why Is ImmunoGen (IMGN) Stock Up 81% Today?
Via InvestorPlace
AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal
Via Investor's Business Daily
Mastering Market Trends: The 7 Best Blue-Chip Stocks for Today’s Economy
Via InvestorPlace
AbbVie's Lung Cancer Study Shows Encouraging Clinical Benefits In Subtype Of Patients
Via Benzinga
These are the top sectors for blue chip growth in 2024
Via MarketBeat
Topics Economy Intellectual Property
Exposures COVID-19 Intellectual Property Interest Rates
J&J, Gilead, BMS: A look at undervalued dividend payers
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.